AGC Biologics becomes first manufacturer of newly approved Libmeldy
![](/46/pdcnewsitem/11/02/75/HLN00CPO%20AGC%20Biologics-Milan990x525.jpg)
AGC Biologic's Milan facility
The CDMO will use its gene and cell therapy commercial expertise to bring "remarkable innovation" to young eligible patients
Orchard Therapeutics has selected biopharmaceutical contract development and manufacturing organization (CDMO) AGC Biologics as the first manufacturer of its lentiviral vector-based gene therapy, Libmeldy.
The drug, which was recently approved by the European Commission as a one-time therapy for eligible patients with early-onset Metachromatic Leukodystrophy (MLD), will be manufactured at the CDMO's Milan facility.
Orchard Therapeutics is already underway with EU launch preparations to support commercial-scale drug manufacturing at the AGC Biologics Milan facility.
AGC Biologics Chief Business Officer, Mark Womack, said: “We’re very proud to be one of few cell and gene therapy CDMOs with commercial experience – Libmeldy being the third commercial product we’ve manufactured – and we look forward to continuing our partnership with Orchard to provide this life-changing therapy to those affected by MLD.”
The CDMO has been part of the entire clinical journey of Libmeldy (also known as OTL-200), from the first treated patient all the way to market approval. The company will continue its partnership with Orchard Therapeutics by manufacturing both lentiviral vector and drug product.
![AGC Biologics](https://www.cphi-online.com/c272056th_S-comp272056.jpg)
Related News
-
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Women in Pharma Anniversary: Celebrating Our Heroines of Pharma
Our Women in Pharma interview series is approaching its 1-year anniversary this month, and to celebrate, we are highlighting the Heroines of Pharma that our very own Women in Pharma admire. -
News Sanofi gains rare disease therapy in acquisition of Inhibrx for US$1.7 billion
Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News Sanofi to collaborate with OpenAI and Formation Bio
Pharmaceutical giant Sanofi have announced a collaboration with Formation Bio and OpenAI to build AI-powered software for accelerated drug development. -
News AstraZeneca to build billion-dollar ADC manufacturing site in Singapore
The British-Swedish drugmaker has announced plans to build a US$1.5 billion facility in Singapore for the manufacturing of antibody–drug conjugates (ADCs) to complement their existing cancer drug portfolio. -
News Women in Pharma: Delivering personal and professional success
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Eisai begins US FDA rolling submission for Alzheimer’s drug Leqembi
Japanese drugmaker Eisai, in partnership with Biogen, have announced that they have begun submitting data on a rolling basis to the US FDA for a marketing application of a subcutaneous injectable form of Alzheimer’s drug Leqembi.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance